Microbiome Therapeutics Market Report – Research, Industry Analysis Reports and Market Demands

Global Microbiome Therapeutics Market Growth 2019-2024

Request for Sample of this report

Buy now

Table of Content

2019-2024 Global Microbiome Therapeutics Consumption Market Report

1 Scope of the Report

2 Executive Summary

2.1 World Market Overview
- 2.1.1 Global Microbiome Therapeutics Consumption 2014-2024
- 2.1.2 Microbiome Therapeutics Consumption CAGR by Region
2.2 Microbiome Therapeutics Segment by Type
- 2.2.1 Type I
- 2.2.2 Type II
2.3 Microbiome Therapeutics Consumption by Type
- 2.3.1 Global Microbiome Therapeutics Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Microbiome Therapeutics Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Microbiome Therapeutics Sale Price by Type (2014-2019)
2.4 Microbiome Therapeutics Segment by Application
- 2.4.1 Inflammatory Bowel Disease (IBD)
- 2.4.2 Orphan Drug
- 2.4.3 Immuno-oncology
- 2.4.4 Others
2.5 Microbiome Therapeutics Consumption by Application
- 2.5.1 Global Microbiome Therapeutics Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Microbiome Therapeutics Value and Market Share by Application (2014-2019)
- 2.5.3 Global Microbiome Therapeutics Sale Price by Application (2014-2019)

3 Global Microbiome Therapeutics by Players

3.1 Global Microbiome Therapeutics Sales Market Share by Players
- 3.1.1 Global Microbiome Therapeutics Sales by Players (2017-2019)
- 3.1.2 Global Microbiome Therapeutics Sales Market Share by Players (2017-2019)
3.2 Global Microbiome Therapeutics Revenue Market Share by Players
- 3.2.1 Global Microbiome Therapeutics Revenue by Players (2017-2019)
- 3.2.2 Global Microbiome Therapeutics Revenue Market Share by Players (2017-2019)
3.3 Global Microbiome Therapeutics Sale Price by Players
3.4 Global Microbiome Therapeutics Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Microbiome Therapeutics Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Microbiome Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Microbiome Therapeutics by Regions

4.1 Microbiome Therapeutics by Regions
- 4.1.1 Global Microbiome Therapeutics Consumption by Regions
- 4.1.2 Global Microbiome Therapeutics Value by Regions
4.2 Americas Microbiome Therapeutics Consumption Growth
4.3 APAC Microbiome Therapeutics Consumption Growth
4.4 Europe Microbiome Therapeutics Consumption Growth
4.5 Middle East & Africa Microbiome Therapeutics Consumption Growth

5 Americas

5.1 Americas Microbiome Therapeutics Consumption by Countries
- 5.1.1 Americas Microbiome Therapeutics Consumption by Countries (2014-2019)
- 5.1.2 Americas Microbiome Therapeutics Value by Countries (2014-2019)
5.2 Americas Microbiome Therapeutics Consumption by Type
5.3 Americas Microbiome Therapeutics Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Microbiome Therapeutics Consumption by Countries
- 6.1.1 APAC Microbiome Therapeutics Consumption by Countries (2014-2019)
- 6.1.2 APAC Microbiome Therapeutics Value by Countries (2014-2019)
6.2 APAC Microbiome Therapeutics Consumption by Type
6.3 APAC Microbiome Therapeutics Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe Microbiome Therapeutics by Countries
- 7.1.1 Europe Microbiome Therapeutics Consumption by Countries (2014-2019)
- 7.1.2 Europe Microbiome Therapeutics Value by Countries (2014-2019)
7.2 Europe Microbiome Therapeutics Consumption by Type
7.3 Europe Microbiome Therapeutics Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Microbiome Therapeutics by Countries
- 8.1.1 Middle East & Africa Microbiome Therapeutics Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Microbiome Therapeutics Value by Countries (2014-2019)
8.2 Middle East & Africa Microbiome Therapeutics Consumption by Type
8.3 Middle East & Africa Microbiome Therapeutics Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
10.2 Microbiome Therapeutics Distributors
10.3 Microbiome Therapeutics Customer

11 Global Microbiome Therapeutics Market Forecast

11.1 Global Microbiome Therapeutics Consumption Forecast (2019-2024)
11.2 Global Microbiome Therapeutics Forecast by Regions
- 11.2.1 Global Microbiome Therapeutics Forecast by Regions (2019-2024)
- 11.2.2 Global Microbiome Therapeutics Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
11.7 Global Microbiome Therapeutics Forecast by Type
11.8 Global Microbiome Therapeutics Forecast by Application

12 Key Players Analysis

13 Research Findings and Conclusion

Description

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

In the last several years, global market of Microbiome Therapeutics developed rapidly, with an average growth rate of 98%. In 2017, Global Market Size of Microbiome Therapeutics is nearly 14 M USD.
For developing product, there are 2 products in Phase 3, 7 products in Phase 2, 8 products in Phase 1 and 17 products in Preclinical. The total investment for Microbiome Therapeutics developing is around 293 M USD in 2017.
The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI in 2016 is about 52%, and the proportion is in Increase trend from 2012 to 2016.

According to this study, over the next five years the Microbiome Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Microbiome Therapeutics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Microbiome Therapeutics market by product type, application, key manufacturers and key regions and countries.

This study considers the Microbiome Therapeutics value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Type I
Type II
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Osel
Metabogen

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Microbiome Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Microbiome Therapeutics market by identifying its various subsegments.
Focuses on the key global Microbiome Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Microbiome Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Microbiome Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.